abstract |
Provided herein is a combination therapy for treating cancer with BRAF mutations comprising administrating to a subject an effective amount of osimertinib or a salt thereof, cobimetinib or a salt thereof, and palbociclib or a salt thereof. Also provided are compositions and kits related to the combination therapy. |